The content on this site is intended for healthcare professionals only
Dr Shanu Modi presents her findings from a phase 3 randomised study, known as DESTINY-Breast04, investigating trastuzumab deruxtecan versus treatment of physician’s choice in patients (pts) with HER2-low unresectable and or metastatic breast cancer.
She discusses and outlines the methodology of the study.
Dr Modi then goes onto to explain the results and key findings which were that DESTINY-Breast 04 is the first phase 3 trial of a HER-2 directed therapy in patients with HER2-low mBC to show a statistically meaningful benefit in PFS and OS compared to the standard of care treatment, regardless of HR status, with a generally manageable safety profile.
Watch our interview with Dr Modi on the study here
Watch Dr Meisel comment on the study here
Read the news story here
ELCC 2024: Latest in EGFR mutant lung cancer; exon 20 mutation focus
Potential benefit to response rates from trastuzumab added to perioperative chemotherapy for patients with HER-2+ GC
ADCLEC.syn1 and CD33-CARS in humanised acute myeloid leukaemia models shows promising efficacy
Breast and emerging indications for IORT
The advantages of IORT for early breast cancer treatment
The pros and cons of breast IORT and ultra hypofractionation (FR)
SOFT study: Clinical relevance of genomic alterations in premenopausal HR+, HER2- early breast cancer
Global adoption of single-shot targeted IORT for breast cancer
The TARGIT-A randomised trial: TARGIT-IORT versus whole breast radiation therapy: long-term local control and survival
